Who Owns Science?

November 6, 2018

This simple three-word question is at the heart of many problems within the dietary supplement industry. I contend the lack of a firm grasp of the answer lends itself to unintentional, yet unavoidable harm. I also argue the problem has become so complicated the solution is repeatedly growing the opposite of science – commoditization. What we all too frequently see is a race to the bottom, rather than an elevation of our products and brands.

In the dietary supplement industry, the issue behind the ownership of science is particularly troublesome for a variety of reasons including:

The ability to patent the products provided is inherently difficult.

  • The industry is committed to the idea that science, not testimonials, is the basis for evidentiary proof of efficacy.
  • What works for one person in one manner is not necessarily going to accomplish the same on another. Small population studies allow for a greater possibility that this differentiation will yield conflicting results in similar studies.
  • Borrowed science is rampant and unchecked. Borrowed science deters innovative science and provides for a generic offering as opposed to unique advancements.
  • To date, despite complaints but few actual deterrents, companies often feel emboldened to use borrowed science. There are signs that this might actually change with this past week’s announced suits by Amarin against two dietary supplement companies that it alleges tried to leverage its recently concluded drug study for their supplement products. Amarin though is in slightly different IP and regulatory position than most supplement companies.

What are some answers to advancing science in the supplement industry?

  • As an industry, recognize companies that spend on Research & Development.
  • Disallow borrowed science and mandate attribution.
  • Companies should take more significant advantage of R&D incentives offered by governments and research institutions.
  • Pool resources to maximize the efficiency of scale of research.

How does science go wrong in the dietary supplement industry? Money, or the lack of same, is the critical component to definitive success or failure of science in almost any industry. Pharmaceutical or supplement, the necessity for larger population studies is often essential to ensure a more certain outcome. The line between the effectiveness of some dietary supplements and pharmaceutical counterparts is sometimes blurred as many supplements have significant physiological impact. The line between what can be said, or not said, is not blurred, especially with well developed clinical research programs.

However, the inability to utilize accurate language when it is justified due to the structure function claim versus health claim environment frequently makes it a necessity to market a product to a less than optimal benefit outcome. One clear example of this is CoQ10. CoQ10 has been effectively being marketed and used to treat Congestive Heart Failure in many parts of the world as a pharmaceutical product for over 50 years. The ingredient was first discovered in 1957 but not commercially available until the 1970’s. Significant clinical research occurred in the 1980’s, and the popularity of the drug in Japan allowed it to become one of the top 5 prescribed pharmaceutical products in Japan.

In 2014, two trials involving Congestive Heart Failure outcomes were conducted. Trust Transparency Center discussed the Paradigm-HF and Q-Symbio studies in more detail in an earlier post (https://trusttransparency.com/when-a-supplement-outperforms-a-drug/ ). The Paradigm-HF study supported a combination pharmaceutical product, Entresto. The Q-Symbio supported CoQ10. The outcome of the Q-Symbio trial showed more significant benefit for CHF patients than Entresto. Today CoQ10 is still not allowed to be marketed for its possible benefit for CHF patients. The monthly cost for the studied dose of CoQ10 is approximately $12/month. Entresto is now a $5B product. The monthly cost for Entresto is approximately $500/month. Finally, Entresto is involved with an FDA advised voluntary recall because N-nitrosodimethylamine (NDMA), a known carcinogen, has been identified as being present in the supply (https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm613532.htm).

The dietary supplement industry is continually decreasing its level of spending on Research and Development. This trend should and can stop with adequate cooperative approaches that provide a recognizable ROI. Proven benefits in health care should be recognized whether or not they come from pharmaceutical or supplements. Regardless of who owns science, we as a society should benefit.

Anthony Reyes
Author: Anthony Reyes

Unlock the Power of Transparency: Schedule a Meeting Now

Ready to Illuminate Your Path?
Partner with Trust Transparency Today.

Get inTouch

Lori Diez

Lori Diez combines compassion and excellence to lead organizations to their next level. A small-town Texas childhood taught her the value of hard work and relationships, which she uses to foster teamwork that brings results that have transformed cultures and programs to their highest potential. Her successful career in pharmaceutical and nutraceutical sales leadership and event hosting has prepared her to deliver results as the COO of TrustTransparency, where she uses her industry knowledge to ensure that the company’s operations run smoothly as they support nutraceutical companies in their mission to help others. Lori’s passion for charity reflects her belief that individuals working together can change the world, no matter how small their contribution to the effort. This year, she looks forward to continuing over a decade of service at the Houston Livestock Show And Rodeo, where she will be the Chairman of the Livestock Committee.

Conference Handouts

Conference Handouts

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 Case Study

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 (1)

Statin Q10 Effect Case Study

Statin Q10 Effect Case Study

Schedule Consultation with Trust Transparency

Glynnda Steinford

Glynnda Steinford, Trust Transparency Consulting’s Director of Customer Relations, brings over four decades of healthcare experience to her vital role in client engagement and relationship building. Her diverse background spans from administering medical groups to impactful stints in pharmaceutical and nutraceutical sales, all underlined by her degree in Healthcare Administration.

At the heart of Glynnda’s work is her talent for nurturing long-term connections, a skill she leverages to enhance client experiences and partnerships within the consultancy. Beyond her professional commitments, she enjoys life’s simple pleasures, whether it’s her love for cats and cooking or her ventures into golf, always prioritizing cherished moments with family and friends. Her personal interests echo the dedication and warmth she extends in her professional network, making her an invaluable asset to the team.

Caiti Dowden

Caiti Dowden stands as a crucial pillar at Trust Transparency Consulting, bringing invaluable insight and expertise to her role as Senior Executive Assistant’ since her start in 2018. With an academic background from Sam Houston University and a career shift from education to the nutraceutical sphere in 2010, Caiti has cultivated a sharp acumen for dissecting industry trends and bolstering strategic decision-making.

Her transition from Data Analyst reflects her growth and deep understanding of the business landscape. Caiti’s commitment goes beyond professional excellence; she thrives on balance, drawing from her rich life outside of work to enhance her organizational contributions. Whether it’s family time, volunteering, or rooting for Houston’s sports teams, she believes in embracing experiences to fuel her professional creativity and insight.

In her current role, Caiti’s dedication to dynamic business analysis and operational support proves her to be an irreplaceable asset to our team, embodying the synergy of personal enrichment and professional success.

Pam Hilpert

Pam Hilpert, Chief of Staff at Trust Transparency Consulting, has been instrumental in the firm since its inception, leveraging her 17 years of accounting experience, including a significant tenure in the nutrition sector. Her collaboration with Scott Steinford spans various successful ventures, emphasizing her integral role in the company’s financial and strategic initiatives.

An alumnus of Sam Houston State University, Pam holds degrees in both Business Administration and Accounting, as well as an MBA, adding academic heft to her practical industry insights. Beyond her professional prowess, Pam is passionate about family, enjoys live music, delves into quilting, and volunteers at her church, reflecting her well-rounded life.

Her multifaceted expertise and longstanding dedication make Pam a cornerstone of Trust Transparency Consulting’s operational strength and team unity.

Scott Steinford

Scott Steinford, a trailblazer in strategic leadership, boasts a certified M&A background, having navigated companies from their genesis to industry prominence. His brainchild, Trust Transparency Consulting, born in 2007, stands as a testament to his dedication to ethical business practices and strategic foresight, offering industry stakeholders invaluable guidance.

Beyond founding and steering companies, Scott has enriched the business landscape with his insightful keynotes and prolific written contributions, emphasizing his commitment to elevating industry standards. His executive tenure shines in roles as CEO or President of for-profits like ZMC-USA and Doctor’s Best, extending to significant contributions in non-profit sectors.

Notably, Scott’s influence is a driving force in the CoQ10 market, where his leadership has significantly bolstered the ingredient’s global presence. His roles in various capacities, including as a New Hope Ambassador, keep the community informed, providing in-depth industry reports and insights.

An active advocate within professional associations and an Editorial Advisor for leading industry publications, Scott’s expertise is both recognized and sought after. With academic roots in Pre-Law and a Master’s in Law, his journey transcends textbooks, embodying real-world business acumen and transformative leadership.

Scott Steinford merges visionary entrepreneurship with principled leadership, creating a legacy of innovation, growth, and unwavering commitment to industry excellence.